Serina Therapeutics Inc (SER)

Serina Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	3.15	3.15	0.59	0.14	0.36	1.73
Revenue Growth (YoY)	410.71%	433.14%	310.76%	-60.11%	-79.11%	23.78%
Cost of Revenue	-0	0	0	0.02	0.03	0.24
Gross Profit	3.15	3.15	0.59	0.13	0.34	1.48
Selling, General & Admin	3.12	3.89	1.29	6.71	6.72	8.14
Research & Development	3.32	2.39	1.57	1.46	3.71	5.9
Other Operating Expenses	0	0	0	-0.55	-0.11	0
Operating Expenses	6.44	6.28	2.86	7.61	10.33	14.04
Operating Income	-3.29	-3.13	-2.27	-7.49	-10	-12.56
Interest Expense / Income	-0.44	0.56	0.02	1.1	0.4	-0.03
Other Expense / Income	-1.96	-8.96	0.4	0.09	0.47	-0.52
Pretax Income	-0.89	5.27	-2.68	-8.68	-10.87	-12.01
Income Tax	0	0	0	0	0	0.15
Net Income	-0.89	5.27	-2.68	-8.68	-10.87	-12.15
Shares Outstanding (Basic)	3	2	2	1	1	1
Shares Outstanding (Diluted)	3	4	2	1	1	1
Shares Change	-67.44%	86.72%	99.12%	0.58%	1.07%	6.75%
EPS (Basic)	2.08	2.30	-1.25	-8.09	-10.20	-11.61
EPS (Diluted)	1.25	1.46	-1.25	-8.09	-10.20	-11.61
EPS Growth	-11.83%	-	-	-	-	-
Free Cash Flow	-2.71	-2.98	-2.09	-7.86	-7.84	-10.8
Free Cash Flow Per Share	-0.97	-1.30	-0.97	-7.29	-7.32	-10.19
Gross Margin	100.03%	100.00%	100.00%	86.81%	92.80%	85.88%
Operating Margin	-104.61%	-99.18%	-383.83%	-5197.92%	-2768.70%	-726.79%
Profit Margin	-28.27%	167.11%	-453.44%	-6024.31%	-3009.70%	-703.36%
Free Cash Flow Margin	-85.98%	-94.53%	-352.55%	-5454.86%	-2170.91%	-625.06%
EBITDA	-1.03	6.09	-2.45	-7.45	-9.21	-11.08
EBITDA Margin	-32.83%	193.13%	-415.04%	-5171.53%	-2550.14%	-641.44%
Depreciation & Amortization	0.3	0.26	0.21	0.13	1.26	0.95
EBIT	-1.33	5.83	-2.67	-7.58	-10.46	-12.04
EBIT Margin	-42.34%	184.81%	-450.76%	-5262.50%	-2897.78%	-696.47%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).